ArticleAnnals of laboratory medicine2020
Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting.
Article in Annals of laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Contemporary Challenges and Strategies for Diagnosing and Managing in Type 2 Myocardial Infarction: A Narrative Review.Journal of personalized medicine · 2026Review
- Uncovering the pivotal role of MYO6 in myocardial infarction: a multimodally validated diagnostic biomarker and immunotherapeutic target.Frontiers in immunology · 2026Article
- Diagnostic performance and risk assessment of combined copeptin and high-sensitivity cardiac troponin I in Chinese emergency department.International journal of cardiology. Heart & vasculature · 2025Article
- Diagnostic Value and Short-Term Prognosis Assessment of Copeptin in Non-ST-Elevation Acute Coronary Syndrome.Journal of cardiovascular translational research · 2025Article
- Circular RNAs as Novel Biomarkers and Application in Cardiovascular Diseases.Advances in experimental medicine and biology · 2025Review
- Chronic Kidney Disease Associated with Ischemic Heart Disease: To What Extent Do Biomarkers Help?Life (Basel, Switzerland) · 2023Review
- Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children.Pharmaceutics · 2023Review
- Spexin level in acute myocardial infarction in the emergency department.Journal of medical biochemistry · 2023Article
- Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice.Molecular biology reports · 2023Review
- Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment.Life (Basel, Switzerland) · 2022Review
- The value of Copeptin, myocardial fatty acid-binding protein and myocardial markers in the early diagnosis of acute myocardial infarction.American journal of translational research · 2022Article
- Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2022Review
- Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients.Journal of cardiovascular development and disease · 2021Review
- Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges.Diagnostics (Basel, Switzerland) · 2021Review
- The effect of emergency nursing on the mental health and limb function recovery of myocardial infarction patients.American journal of translational research · 2021Article
- Detection of circRNA Biomarker for Acute Myocardial Infarction Based on System Biological Analysis of RNA Expression.Frontiers in genetics · 2021Article
- The Biomarkers for Acute Myocardial Infarction and Heart Failure.BioMed research international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapid and accurate diagnosis of acute myocardial infarction (AMI) is critical for initiating effective treatment and achieving better prognosis. We investigated the performance of copeptin for early diagnosis of AMI, in comparison with creatine kinase myocardial band (CK-MB) and troponin I (TnI).
methodsWe prospectively enrolled 271 patients presenting with chest pain (within six hours of onset), suggestive of acute coronary syndrome, at an emergency department (ED). Serum CK-MB, TnI, and copeptin levels were measured. The diagnostic performance of CK-MB, TnI, and copeptin, alone and in combination, for AMI was assessed by ROC curve analysis by comparing the area under the curve (AUC). Sensitivity, specificity, negative predictive value, and positive predictive value of each marker were obtained, and the characteristics of each marker were analyzed.
resultsThe patients were diagnosed as having ST elevation myocardial infarction (STEMI; N=43), non-ST elevation myocardial infarction (NSTEMI; N=25), unstable angina (N=78), or other diseases (N=125). AUC comparisons showed copeptin had significantly better diagnostic performance than TnI in patients with chest pain within two hours of onset (AMI:
conclusionsThe combination of TnI and copeptin improves AMI diagnostic performance in patients with early-onset chest pain in an ED setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.